⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428622 | 1.00 | — | — | |
| SCHEMBL24116900 | 1.00 | — | — | |
| SCHEMBL831212 | 0.79 | — | — | |
| SCHEMBL11036382 | 0.79 | — | — | |
| SCHEMBL11036377 | 0.79 | — | — | |
| SCHEMBL13531532 | 0.79 | — | — | |
| SCHEMBL831211 | 0.79 | — | — | |
| SCHEMBL7424929 | 0.78 | NPSR1 (0.50) | — | |
| SCHEMBL7424926 | 0.78 | NPSR1 (0.50) | — | |
| SCHEMBL7913300 | 0.78 | NPSR1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | NOVARTIS AG (CH) | 2025-07-22 | — | — | US | disclosed |
| CN-115836076-B | Compounds as CAV1.2 activators | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250051345-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2025-02-13 | — | — | US | disclosed |
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4448533-A1 | <SUP2/>? <SUB2/>?V?PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CA1.2 ACTIVATORS | Novartis AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118510782-A | As CaV1.2 Pyridine-3-carboxylic acid ester Compounds of activators | 诺华股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11919911-B2 | Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators | NOVARTIS AG (CH) | 2024-03-05 | — | — | US | disclosed |
| CN-111491935-B | Novel analogs as modulators of androgen and glucocorticoid receptors | 昂科斯特拉公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023111799-A1 | PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-11453660-B2 | Androgen receptor and glucocorticoid receptor modulators | ONCOSTELLAE, S.L. | 2022-09-27 | — | — | US | disclosed |
| US-20210395261-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| WO-2021255607-A1 | METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATES AND METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATES AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253180-A1 | METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-4, 5, 6, 7-TETRAHYDRO-1H-CYCLOPENTA [B] PYRIDINE-3-CARBOXYLATE AND METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-1, 4, 5, 7-TETRAHYDROFURO [3, 4-B] PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| CN-111491935-A | Novel analogs as androgen receptor and glucocorticoid receptor modulators | 昂科斯特拉公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-0233015-B1 | 1,4-Dihydropyridines | WYETH JOHN & BROTHER LTD (GB) | 1995-10-18 | — | — | EP | disclosed |
| EP-0233015-A2 | 1,4-Dihydropyridines | JOHN WYETH & BROTHER LIMITED (GB) | 1987-08-19 | — | — | EP | disclosed |
| US-4686217-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | FISONS PLC (GB) | 1987-08-11 | — | — | US | disclosed |
| US-4607041-A | CARDIOTONIC AGENTS | FISONS PLC (GB) | 1986-08-19 | — | — | US | disclosed |
| EP-0125803-A2 | Pharmaceutically active dihydropyridines | FISONS plc (GB) | 1984-11-21 | — | — | EP | disclosed |